Arch Orthop Trauma Surg (2013) 133:153–165
DOI 10.1007/s00402-012-1641-1


Can platelet-rich plasma (P...

Bone healing
Complications relating to bone healing often arise from the
extensive formation of fibrocartilage, result...
Arch Orthop Trauma Surg (2013) 133:153–165

(TGF-b1, -b2, -b3) and bone morphogenetic proteins (BMP),
fibroblast growth fac...

most potent of the two, exhibiting high expression within
the proliferative, hypertrophic, and mineralization phases
Arch Orthop Trauma Surg (2013) 133:153–165


Fig. 1 Evidence for growth factor relationships to the stages within the ...

protocols [102], however, EDTA has not been traditionally
recommended for use due to the potential for irreversible
Arch Orthop Trauma Surg (2013) 133:153–165

around a sevenfold increase in leukocytes [120]. Castillo
et al. [108] reporte...

Arch Orthop Trauma Surg (2013) 133:153–165

Fig. 2 Platelet secreted growth
factor interactions with major
cell types...
Arch Orthop Trauma Surg (2013) 133:153–165

With the current focus on platelet concentration, the
actual volume of PRP to ...
14. Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic
biology and clinical correlates. Blood Rev 23(4):177–...
Arch Orthop Trauma Surg (2013) 133:153–165
49. Urist MR (1965) Bone: formation by autoinduction. Science
















Arch Orthop Trauma Surg (2013) 13...
Arch Orthop Trauma Surg (2013) 133:153–165
118. Weisel JW (2007) Structure of fibrin: impact on clot stability.
J Thromb Ha...
Upcoming SlideShare
Loading in …5

Can platelet-rich plasma (PRP) improve bone healing? A comparison between the theory and experimental outcomes.


Published on

Arch Orthop Trauma Surg. 2013 Feb;133(2):153-65. doi: 10.1007/s00402-012-1641-1. Epub 2012 Nov 30.
Can platelet-rich plasma (PRP) improve bone healing? A comparison between the theory and experimental outcomes.
Malhotra A, Pelletier MH, Yu Y, Walsh WR.
Surgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, The University of New South Wales, Sydney, Australia.

Published in: Health & Medicine, Technology
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Can platelet-rich plasma (PRP) improve bone healing? A comparison between the theory and experimental outcomes.

  1. 1. Arch Orthop Trauma Surg (2013) 133:153–165 DOI 10.1007/s00402-012-1641-1 ORTHOPAEDIC SURGERY Can platelet-rich plasma (PRP) improve bone healing? A comparison between the theory and experimental outcomes Angad Malhotra • Matthew H. Pelletier Yan Yu • William R. Walsh • Received: 12 July 2012 / Published online: 30 November 2012 Ó Springer-Verlag Berlin Heidelberg 2012 Abstract The increased concentration of platelets within platelet-rich plasma (PRP) provides a vehicle to deliver supra-physiologic concentrations of growth factors to an injury site, possibly accelerating or otherwise improving connective tissue regeneration. This potential benefit has led to the application of PRP in several applications; however, inconsistent results have limited widespread adoption in bone healing. This review provides a core understanding of the bone healing mechanisms, and corresponds this to the factors present in PRP. In addition, the current state of the art of PRP preparation, the key aspects that may influence its effectiveness, and treatment outcomes as they relate specifically to bone defect healing are presented. Although PRP does have a sound scientific basis, its use for bone healing appears only beneficial when used in combination with osteoconductive scaffolds; however, neither allograft nor autograft appear to be appropriate carriers. Aggressive processing techniques and very high concentrations of PRP may not improve healing outcomes. Moreover, many other variables exist in PRP preparation and use that influence its efficacy; the effect of these variables should be understood when considering PRP use. This review includes the essentials of what has been established, what is currently missing in the literature, and recommendations for future directions. A. Malhotra Á M. H. Pelletier Á Y. Yu Á W. R. Walsh (&) Surgical and Orthopaedic Research Laboratories, Prince of Wales Clinical School, The University of New South Wales, Sydney, Australia e-mail: A. Malhotra e-mail: M. H. Pelletier e-mail: Keywords Platelet-rich plasma Á Bone Á Bone healing Á Growth factors Á Tissue engineering Introduction Healthy bone has the capacity to repair and remodel itself, however, complications continue to impair functional repair resulting in delayed healing and non-unions. In an attempt to reduce the risk of complications, surgical intervention is frequently undertaken for trauma cases presenting moderate to massive loss of bone stock, soft tissue damage, disruption of surrounding vasculature, and/or infection. The standard surgical technique for bone repair has previously been achieved via stable fixation in combination with the gold standard of autogenous bone grafting [1]; however, the associated risk of donor site morbidity, increased operative time, blood loss, and length of hospitalization have encouraged the continual investigation into alternatives [2]. Since the reported success of platelet-rich plasma (PRP) combined with autograft in treating mandibular defects [3], PRP has found increasing enthusiasm across a diverse range of fields. Similarly, it presents yet another ambitious option for bone healing. Despite the hype, contrasting surgical outcomes compounded with conflicting terminology and descriptions [4, 5] have limited the widespread adoption of PRP. This review presents the basic science of bone healing and platelets, thus providing a logical basis to discuss findings previously reported in animal and human studies. In addition, current techniques, terminology, and practical considerations are reviewed to provide a clearer indication for the use of PRP in bone healing specifically. 123
  2. 2. 154 Bone healing Complications relating to bone healing often arise from the extensive formation of fibrocartilage, resulting in delayed unions or non-unions affecting approximately 5–10 % of cases. Failure to heal within 3 months is considered delayed, although non-union is considered as a failure to unite within 6–9 months [6, 7]; however, due to the lack of investigation parameters available other than radiology and clinical appearance, no consensus exists on the point of actually diagnosing such healing complications. Cases requiring surgical intervention typically heal via the endochondral ossification pathway [8], which is generally divided into four consecutive, but overlapping phases: hematoma formation, soft callus formation, hard callus formation, and remodeling. This process is initiated by cells of the immune system, whereby a hematoma forms, and inflammation ensues. Following this, neovascularization and fibrous tissue formation leads to the development of hyaline cartilage, forming the soft callus. This soft callus undergoes cartilage mineralization and subsequent formation of woven bone which defines the hard callus. Finally, the conversion of the hard callus to functional lamellar bone progresses via continuous bone remodeling [9]. The inflammatory phase of bone healing is regulated by pro-inflammatory cytokines secreted by invading macrophage, polymorphonuclear leukocytes and lymphocytes [8]. The expression of tumor necrosis factor-a (TNF-a) and interleukin-1 (IL-1) peaks at 24 h post-injury, activating secondary signaling pathways involved in the downstream processes involved in callus formation [10]. Platelets are activated during this early phase, and in combination with fibrin, form the hematoma. Upon activation, platelets secrete a variety of cytokines which have been attributed to successful hard and soft tissue development and regeneration [11]. Typically, many of these molecules are produced and secreted by cells from a variety of tissues, in which most circulate within the blood. In the case of bone healing, platelet activation and subsequent degranulation provides a burst of cytokines directly at the injury site. Although delayed bone healing and non-unions may be exacerbated by a variety of interpersonal factors, including pre-existing diseases, medication, cigarette smoking, age, and infection, most commonly these healing complications are associated with vascularization issues and mechanical instability [12]. The role of specific growth factors relate to these aspects, being angiogenesis and endochondral bone formation. Platelets The platelet life cycle begins with the differentiation of hematopoietic stems cells on the endosteal bone surface, 123 Arch Orthop Trauma Surg (2013) 133:153–165 producing megakaryocyte progenitors that migrate to the blood vessels within the bone marrow. The formation of proplatelet extensions from megakaryocytes into the vessel, and subsequent proplatelet maturation results in *2.5 lm proplatelet fragments being released within the vasculature to circulate as platelets [13]. Within platelets, three main platelet secretory granules exist: a-granules; dense granules; and lysosomes. The most prevalent a-granules comprise approximately 10 % of the platelet volume, and upon degranulation, deliver hundreds of proteins either into the extracellular matrix or expressed as membrane bound proteins on the surface. These proteins are composed of an array of chemotactic and mitogenic growth factors, hemostatic factors, adhesion molecules, and other cytokines [14]. Dense granules perform a primary role via the release of proaggregating factors, such as calcium ions and adenosine diphosphate (ADP) [15], and lysosomes are involved in the release of clearing factors in the form of digestive enzymes [16]. Selectively, these molecules have crucial and established roles in the regulation of tissue regeneration. Platelet adhesion to endothelial cells is promoted by adhesive glycoproteins secreted from a-granules, such as fibronectin, vitronectin, thrombospondin and von Willebrand factor [14, 16], with fibronectin and vitronectin also promoting osteogenic cell adhesion and spreading [17]. Although complex synergistic connections exist between the various molecules [18], the release of specific growth factors has primarily driven the prospect of platelets for tissue regeneration. Growth factors Growth factors generally perform their function through the binding of ligands to the associated extracellular receptors on target cells, leading to intracellular cytoplasmic proteins attaching to the phosphorylated tyrosine. Although independent intracellular activation pathways exist [19], ligand binding to the receptor tyrosine kinase is most commonly associated with the downstream intracellular signaling via growth factors. This process is followed by a series of phosphorylation and activation steps of protein kinases within the cytoplasm. The final step involves the translocation of a phosphorylated kinase to the cell nucleus, phosphorylating transcription factors necessary for the transcription of genes [20, 21]. Ultimately, this complex pathway results in the stimulation, or inhibition, of cell migration, proliferation and differentiation. Growth factors of particular relevance to this review are platelet-derived growth factor (PDGF-AB, -BB), vascular endothelial growth factor (VEGF-A), hepatocyte growth factor (HGF), the transforming growth factor superfamily, including transforming growth factor b1, b2 and b3
  3. 3. Arch Orthop Trauma Surg (2013) 133:153–165 (TGF-b1, -b2, -b3) and bone morphogenetic proteins (BMP), fibroblast growth factor (FGF), and insulin-like growth factor (IGF). Although these are commonly presented as specific purpose factors, the crosstalk between separate and various signaling pathways are complex and not as easily defined. Platelet-derived growth factor The significance of PDGF is the ability to initiate callus formation through the chemotaxis of mesenchymal stem cells [22], and the chemotaxis and mitogenesis of connective tissue cells, most notably fibroblasts and chondrocytes [23, 24]. Supporting this, the involvement of PDGF in angiogenesis via the promotion of endothelial cell proliferation [25], and the chemotaxis of neutrophil and macrophage which may provide a secondary stage of growth factor release, highlights PDGF as a crucial initiator of bone healing [26]. The three isoforms of PDGF with the most understood roles in bone healing are constructed with A and B chains: PDGF-AA; -AB; -BB; with the associated platelet-derived growth factor receptors (PDGFR) being either a- or b-subunits. Although different isoform binding affinities exist, the A chain is able to bind only to a-receptors, whereas the B chain binds to both a- and b-receptors. Because higher levels of b-receptors are expressed in general than a-receptors, the PDGF-AB and PDGF-BB dimers are considered more potent proteins than the -AA isoform [26], with specifically PDGF-BB gaining increasing attention for bone healing over other PDGF isoforms [27]. As a reference, platelets contain PDGF in a ratio of 60–70 % PDGF-AB, 20–40 % PDGF-BB, and 5–25 % of PDGF-AA [26, 28]. Vascular endothelial growth factor and hepatocyte growth factor Angiogenesis is a highly regulated process with brief periods of action, and then complete inhibition [29]. This process is essential for successful healing by providing oxygen and nutrients to the injured site via the newly formed blood vessels. The significance of VEGF is in its clear role in neovascularization as a potent endothelial chemokine and mitogen. Once VEGF binds to the associated receptors expressed on endothelial cells, a cellular response is induced in which released matrix metalloproteinases (MMP) digest the surrounding extracellular matrix. This matrix degradation allows for the migration and proliferation of vascular endothelial cells essential for the formation of the new blood vessels [30]. Although VEGF target cell receptors are contained primarily on endothelial cells, the expression of VEGF receptors by chondrocytes in the epiphyseal growth plate 155 demonstrates the involvement of VEGF in bone formation, lengthening and endochondral ossification [31, 32]. VEGF release from platelets has been well established [33–35], with additional VEGF release from hypertrophic chondrocytes also assisting in the timely angiogenic signaling necessary for the transition from soft to hard callus [32]. The role of hepatocyte growth factor (HGF) in bone healing is yet to be elucidated. One possibility is an involvement in angiogenesis, where VEGF signaling pathways are activated through the HGF receptor, c-Met, inducing similar endothelial cell responses without competing with the VEGF surface receptors [36]. HGF may also be involved as a positive regulator of angiogenesis by working synergistically with VEGF [36, 37]. Although the role of HGF in osteogenesis is also uncertain, it has been shown to be expressed during bone healing, promoting the osteogenic differentiation of MSC [38], and stimulating BMP signaling through the upregulation of BMP receptors on MSC [39]. Based on the above, the attraction of HGF for bone healing appears to be in the indirect, synergistic roles promoting angiogenesis and osteogenesis. Transforming growth factor b The TGF-b superfamily consists of structurally and functionally related factors regulating many biological processes, including cell growth, differentiation, adhesion, migration and apoptosis. This superfamily has been strongly associated with many of the bone healing processes, and comprises TGF-b (1–3), BMPs, growth differentiation factors (GDF), activins, and inhibins [40]. TGF-b is a polypeptide that stimulates the proliferation of fibroblast and MSC, with three isoforms being expressed in humans, TGF-b (1–3). Although platelets constitute a major source of TGF-b, production by osteoblasts, chondroblasts, and macrophage result in a significant deposit of TGF-b in bone [41]. The commonly recognized role of TGF-b is the promotion of chondrogenesis during endochondral bone formation [42], demonstrated by the high expression in the cartilaginous phase [43, 44]. The osteogenic potential has also been recognized [45], signifying TGF-b as a stimulator of both chondrogenic and osteogenic MSC differentiation [46]. These properties, combined with its involvement in osteoclast apoptosis and inhibition [47], associates TGF-b with the critical early and mid-stage processes in the endochondral bone healing pathway. All three of the isoforms of TGF-b are highly relevant; collectively, their expression has been reported through many of the crucial bone healing processes. TGF-b1 displays a constant moderate expression throughout bone healing, with greater involvement in osteoblast mitosis. In contrast, TGF-b2 and b3 expression peaks strongly during chondrogenesis, with the b2 isoform being possibly the 123
  4. 4. 156 most potent of the two, exhibiting high expression within the proliferative, hypertrophic, and mineralization phases [43, 45, 48]. Since the pioneering work of Urist [49], one of the most cited proteins within the bone healing field has been the family of bone morphogenetic proteins (BMP). BMPs are known to be potent osteoinductive proteins involved in many of the processes related to bone formation and regeneration [50]. Osteoprogenitors, osteoblasts, mesenchymal cells, and chondrocytes deposit BMPs within the extracellular matrix, where these growth factors drive MSC differentiation, particularly down osteogenic lineages [18, 50]. Although evidence supporting the role of BMPs in bone healing exists [51–53], a therapeutic release of BMPs from platelets has yet to be established [54]. Platelets were previously considered to have no true osteoinductive potential as they were thought not to contain any BMPs [55], however, BMP-2, -4, -6 and -7 have been found to be released by platelet concentrates, possibly encouraged by acidic environments [54, 56]. Despite this finding, the therapeutic benefit of these endogenous BMPs is unclear; commercially available exogenous BMP concentrations used for bone healing applications are commonly quoted at three or more orders of magnitude greater than those reportedly released from platelet concentrates [57, 58]. Fibroblast growth factor and insulin-like growth factor Although the members of FGF family are involved in a variety of biological functions, the relevance to bone healing is in the FGF stimulated signaling of MSCs down osteogenic pathways, and in particular osteoblastogenesis [46, 59]. FGF may also have an important role during the remodeling phase of bone healing [60]. Although many FGFs have been identified with differential temporal expression within bone healing, two groups of FGF receptors (FGFR) have particular relevance to bone healing. High expression of both the FGFR1 and FGFR2 on osteoblasts during hard callus remodeling [61] supports the assertion that FGF signaling has an important role in regulating osteoblast mitosis and differentiation [62]. The stimulation of migration and proliferation of endothelial cells by FGF-2 [63] suggests that FGFs may also have beneficial angiogenic properties for bone healing. FGF-2 may have an indirect, synergistic role in angiogenesis, by upregulating VEGF expression [64]. Asahara et al. [65] reported such a synergistic effect when combining VEGF and FGF-2 in an ischemic rabbit hind leg model. More recently, however, Willems et al. [66], failed to show any synergistic angiogenic effect when combining VEGF and FGF-2 with allograft in a rat segmental bone defect model. As with many of the growth factors, the required dose of FGF-2 to induce the intended effect remains unclear. 123 Arch Orthop Trauma Surg (2013) 133:153–165 IGF is sourced from the bone matrix, endothelial cells, osteoblasts, chondrocytes and platelets, with the presence of BMPs possibly stimulating the secretion of IGF. Proliferation and maturation of chondrocytes to hypertrophy is a pivotal process in the endochondral pathway, and is regulated by IGF [11, 67]. IGF may also have a role in the later stages in bone maturation and remodeling [68]. The variety of relevant factors secreted from platelets forms the basic premise for the use of the product loosely defined as PRP for bone healing. Although the platelet lifespan of 8–10 days [13] is considerably less than the timespan of bone healing, growth factor entrapment within the fibrin matrix [69, 70] may facilitate the time release of factors at the healing site; consequently, growth factor action could outlive the platelet. Figure 1 illustrates the relationship between platelet secretory factors to a timeline of the endochondral bone healing process. In brief, after hematoma formation, platelet proinflammatory cytokines, such as interleukin-1, -8, and platelet factor 4 are involved in inflammatory cell chemotaxis and endothelial–leukocyte adhesion [71]. Chondrogenic differentiation of MSC leads to soft callus formation characterized by cartilage formation. Cartilage is calcified before chondrocyte hypertrophy and apoptosis leads to chondroclast released enzymes facilitating matrix degradation. Platelet-derived matrix metalloproteinases (MMP) may also have a role in matrix degradation [72]. Subsequent neoangiogenesis, osteoclast population, and differentiation of osteoprogenitor cells facilitate the remodeling of the callus to structural lamellar bone [8, 73–76]. The growth factors presented relate, where shown, to the stages of endochondral bone healing. Recombinant growth factors Although synergistic and antagonistic growth factor actions are likely to exist, the application of singular exogenous growth factors provides an accessible and convenient source of signaling molecules that have the potential to improve bone healing. Recombinant human bone morphogenetic proteins (rhBMP) have had promising results for bone healing in both preclinical models [57, 77–79] and clinical studies [58, 80], however, the efficacy of its use in all applications remains inconclusive [81, 82]. Although the use of rhBMP has gained the most interest for bone healing, rhPDGF also has also had reported success for similar applications. Recombinant human PDGF-BB (rhPDGF-BB) is also commercially available, and has been reported to have a positive effect for bone formation [83–86]; although, as with many biological therapies, this effect is likely to be dose and time dependent. When comparing rhBMP, rhPDGF, and rhVEGF, Kaipel et al. [51] reported that only rhBMP supported bone regeneration, with both
  5. 5. Arch Orthop Trauma Surg (2013) 133:153–165 157 Fig. 1 Evidence for growth factor relationships to the stages within the endochondral healing pathway Platelet-rich plasma finding led to an increased interest and use of PRP within the oral and maxillofacial surgical fields [89–91]. Since this early adoption during the 1990s, PRP has seen prolific use across an increasing variety of surgical fields, to now include applications ranging from soft tissue healing [92, 93], cosmetic surgery [94, 95], burns [96], nervous tissue [97, 98], and chronic skin ulcers [99]. Although the range of potential applications continues to increase, conclusive indication for the use in bone healing still remains to be established. History PRP production The separation of blood components for surgical application has a long history; the collection of fibrinogen to use as intraoperative fibrin glue aiding topical hemostasis found applications in many clinical settings [87]. Although the advantages of a hemostatic and adhesive fibrin glue are known, in 1994, Tayapongsak [88] reported the formation of the fibrin matrix also supported mandibular bone remodeling by functioning as a cell supporting scaffold. Leading on from this, the identification of platelet secreted growth factors led to the development and use of PRP, initially reported in 1998 by Marx as beneficial for use in bone regeneration of mandibular defects [3]. This positive The production of PRP begins with an autologous blood sample being needle drawn from a clear venipuncture, and mixed with an anticoagulant to prevent clotting. Although a citrate-based anticoagulant may be used, such as sodium citrate or citrate–phosphate–dextrose [100], Acid–citrate– dextrose solution A (ACD-A) is most commonly used in PRP preparations. ACD-A is capable of maintaining the intraplatelet signal transduction mechanisms during PRP preparation, and therefore maintaining the responsiveness of platelets [101]. Ethylenediaminetetraacetic acid (EDTA) has had reported success in minimizing platelet aggregation more effectively for the use with PRP production rhVEGF and rhPDGF failing to improve healing above the fibrin matrix control. The use of recombinant growth factors remains promising, however, as specific temporal expression of different factors has been observed over the time course of bone healing [8, 22, 48], the application of multiple growth factors may more accurately reproduce a normal healing environment. 123
  6. 6. 158 protocols [102], however, EDTA has not been traditionally recommended for use due to the potential for irreversible structural, biochemical and functional damage to platelets [103]. The high level of aggregation inhibition by EDTA may also restrict future platelet activation, a feature essential for therapeutic PRP applications. Although plateletpheresis [104] and filtration [105] methods do exist, PRP is generally collected after the separation of the components of whole blood by table-top centrifugation. The production of PRP by centrifugation was originally achieved by a two-step gradient centrifugation method. In this method, a hard first spin was used to separate the red blood cells (RBC) from the plasma which contained leukocytes, platelets and clotting factor. The plasma was then centrifuged in a second soft spin intended to finely separate the platelets and leukocytes [106], after which PRP was collected. Commonly, and most often with commercially available systems [107, 108], a one-step method is employed where the aim is to separate the RBCs, buffy coat, and plasma into three distinct layers. The buffy coat contains platelets and leukocytes, and is often collected as a PRP. The plasma layer above is often called the platelet poor plasma; however, depending on centrifugation parameters and the collection inefficiency of the technique, this layer may contain a substantial number of platelets. The benefit of using commercial systems over manual methods may be limited to improved ergonomy and repeatability, rather than platelet collection efficiency. Regardless of a manual single- or double-spin technique, the centrifugal forces applied, and length of time at those forces, presents yet another variable; a variable that highly influences the platelet concentration. Clinically, any reduction in time without the loss of quality is obviously desirable, with the range reported in most studies lies within 160–3,0009g for 3–20 min [109]. Although PRP may be defined as a portion of plasma fraction of autologous blood with platelet count above baseline, this definition does not give a full insight into the optimal platelet count of PRP. Many authors still quote a definition of PRP by Marx, as a product with platelet concentration of 1,000 9 109/L in 5 mL of plasma [106]. Normal baseline whole blood platelet count is considered to be around 200 9 109/L, and although studies have reported use of 2–8 times above baseline, a platelet count at 5 times baseline is often mentioned to be of therapeutic benefit [55, 110]. Araki et al. [102] compared various manual single and double-spin preparation methods of PRP, achieving a maximal 20-fold increase using a double-spin technique of 2309g for 10 min, followed by pellet formation during a second spin at 2,3009g for 10 min, and finally pellet resuspension. Although a high platelet concentration seems to be the ultimate goal of PRP, the cost of getting there may be 123 Arch Orthop Trauma Surg (2013) 133:153–165 considerable. Dugrillon et al. [111] reported a decrease in TGF-b release at forces above 8009g when spun for 15 min, suggesting a possible decline in platelet function at high G-forces. Poor growth factor release is often attributed to pre-mature activation and platelet damage during processing; as such, aggressive processing techniques with the aim of very high platelet concentrations may result in a paradoxically inferior PRP. Weibrich et al. [112] studied the effect of platelet concentration on peri-implant bone regeneration, and concluded that platelet concentrations between two- and sixfold increase were beneficial, with no benefit being detected at lower or higher fold increases. Similarly, Graziani et al. [113] reported a 2.5-fold increase was optimal for osteoblast proliferation in vitro, however, all PRP concentrations were still inferior to the positive control of Dulbecco’s modification of Eagle’s medium with 10 % fetal calf serum. The potential of growth factors to transduce a cellular response is limited by the expression of associated receptors on target cells. Therefore, as ligandbinding sites are finite, excessive platelet concentrations resulting in excessive growth factor release may not be beneficial. The activation method of PRP before implantation has not been standardized in practice. The simplest option is to implant the PRP in an anticoagulated state; the theory behind this approach being that PRP will activate when in contact with exposed collagen in damaged tissue. In regard to ex vivo activation, bovine thrombin was previously considered a suitable PRP activator [114], however, associated complications have all but removed it from use for this purpose [115]. The use of calcium chloride has also been reported [116], and may represent a simple, easily available alternative for clot activation. Different agonists, such as ADP, thrombin, and collagen, interact with individual platelet surface receptors, leading to distinct intracellular signaling by messenger molecules to the separate granules [71]. This results in a differential granular release depending on agonist. The thrombin concentration available to the PRP during gel formation also affects the platelet release, rate of fibrin formation, the fibrin structure [117], and clot stability [118]. As such, the production and use of autologous thrombin is gaining popularity. Autologous thrombin is produced by collecting the thrombin containing supernatant of a calcium chloride clotted PRP [119], and presents itself as a useful PRP activator. To date, studies comparing the effect of different PRP activation methods are lacking. Leukocytes and fibrin Leukocyte inclusion and the leukocyte concentration is a factor often overlooked in many studies. PRP collected from the buffy coat layer has been reported to contain
  7. 7. Arch Orthop Trauma Surg (2013) 133:153–165 around a sevenfold increase in leukocytes [120]. Castillo et al. [108] reported 1.7- to 5.6-fold increases in leukocytes from three commercially available systems. Growth factors are produced by neutrophils, monocytes and macrophage, and provide an additional source of growth factors [23, 121]. Platelets also have a role in the recruitment of inflammatory cells, such as neutrophils and monocytes [122]. With regard to immunity, platelets are themselves known to interact directly with viruses, bacteria and fungi, and contain platelet microbicidal proteins within the a-granules [14, 122–124], thus providing supplementary actions to leukocytes. An increase in leukocytes, combined with the view of platelets themselves as innate inflammatory cells with acute host defense functions [122], suggests a PRP product containing leukocytes may also be useful against postoperative infections. A PRP derivative developed by Anitua et al. [125] aims to avoid the pro-inflammatory effects of leukocytes for treating muscle damage. The exclusion of leukocytes for bone healing, especially in cases of open injury, is yet to be fully justified. Fibrin induces angiogenesis by providing a matrix scaffold which supports cell migration and provides chemotactic activity. The structure of a fibrin clot affects its ability to perform as a suitable scaffold for cellular attachment [117], although the binding of thrombin and growth factors to the fibrin fibers also support healing as a standby release mechanism during primary clot degradation [69, 70]. The density and composition of the fibrin matrix is therefore another factor of the PRP [109] not often considered. Figure 2 illustrates a timeline of bone healing through the endochondral pathway, highlighting some of the platelet secreted growth factor interactions with the relevant cell types within the pathway. Terminology Although PRP is a generic term, many terms and acronyms have appeared to differentiate PRP constituents and state of activation, but may be also increasing the confusion. Although many authors urge standardization, the variety of names unfortunately does little to help standardize the product. At minimum, four components of PRP should be reported. Most obviously, reporting the platelet concentration is central in any PRP product. In addition, the leukocyte and fibrinogen concentrations, and activation methods used, should be routinely reported in PRP products [109, 126]. It is clear that these four variables alone allow many possible variants of PRP to be produced; however, provide a simple baseline for comparison. PRP is used in this review as a blanket term, as previous studies often do not mention leukocyte concentration, fibrinogen concentration, and/or activation methods. 159 Practical applications The basic elements for bone tissue engineering are signaling molecules, cells, and matrices [127]. PRP provides signaling molecules in the form of the variety of growth factors, and possibly a cell supporting matrix in the form of the fibrin matrix. When considering the fibrin matrix, when degradation of a scaffold does not align with the rate of bone regeneration, healing may be impaired by either a lack of a scaffold, or an excessive volume of intact scaffold. When treating segmental defects placed in the radius of rabbits, Hokugo et al. [128] reported improved healing when PRP was combined with a biodegradable gelatin hydrogel, compared to either PRP alone or gelatin alone. In addition, they reported that although PRP combined with fibrin outperformed gelatin alone, free PRP was inferior to the gelatin alone, highlighting the need for PRP to be combined with a cell supporting matrix. Although the fibrin clot structure and stability are known factors, the capacity of a PRP gel to act as the sole scaffold does not appear reliable for bone healing. To further facilitate cell attachment, the addition of bone graft substitutes to PRP may be essential for bone applications. This ensures a suitable scaffold exists during healing to support cell attachment. Allogenic and autologous grafts have long been recognized as grafting options. Allogenic demineralized bone matrix (DBM) is known to often have both osteoinductive and osteoconductive potential [129], yet, Ranly et al. [130] reported PRP added to DBM decreased its osteoinductivity. Similarly, Ni et al. [131] reported the combination of DBM and PRP was not beneficial over DBM alone during distraction osteogenesis of rabbit tibia. Depending on the processing, autologous grafts often have osteoinductive, osteoconductive, and osteogenic properties [132]. These three properties encompass the prescribed features for successful tissue healing [127]; hence, the addition of PRP to autogenous graft may not be beneficial. Mooren et al. [133, 134] reported no detectable benefit from the addition of PRP to autogenous grafts in two separate studies in goat critical size frontal bone defects. Aghaloo et al. [135] also reported no detectable advantage of combining PRP to autograft compared to using autograft alone in rabbit calvaria defects. Conversely, Dallari et al. [136] reported the three part combination of allograft, bone marrow-derived stem cells (BMSC), and PRP improved bone regeneration in critical size distal femur defects in rabbits when compared with any combination of only two elements alone. In addition, PRP alone was inferior to either allograft alone or BMSC alone; however, when PRP was combined with either allograft or BMSC, was able to improve the healing response of either component alone. Hakimi et al. [137] 123
  8. 8. 160 Arch Orthop Trauma Surg (2013) 133:153–165 Fig. 2 Platelet secreted growth factor interactions with major cell types within the bone healing timeline also reported a beneficial effect from the combination of autograft and PRP in tibial metaphysis defects in mini-pigs when compared with autograft alone. It is not yet clear whether the addition of PRP to allograft, autologous MSC, or autograft is beneficial. Allogenic and autogenic grafts both have some osteoinductive potential. Although PRP is not considered to be highly osteoinductive in itself, the addition of PRP may be beneficial to grafts lacking osteoinductivity, as in synthetic bone graft substitutes (BGS). As synthetic BGS alone have been shown to support bone healing [138, 139], the addition of biological activity may have the potential to further facilitate or accelerate healing. Kasten et al. [140] treated critical sized diaphyseal radius defects in a rabbit model, and although autologous graft outperformed the test groups, higher bone formation was reported when PRP was combined with hydroxyapatite (HA) as compared to the HA graft alone. Similarly, Kanthan et al. [141] reported PRP was only beneficial when combined with artificial osteoconductive scaffolds for the treatment of non-uniting segmental tibial defects in rabbit. In a clinical case study, Paderni et al. [142] reported using PRP combined with a hydroxyapatite-based bone substitute to treat a bifocal ulnar bone defect. The authors attributed the success of the graft to the factors present in the PRP, combined with the osteoconductive hydroxyapatite scaffold. The addition of bone marrow aspirate to the combination of PRP and synthetic graft has been reported to improve the rate of spinal fusion and stiffness in sheep when compared with 123 the synthetic graft and PRP alone, and even when compared with autograft [143]. PRP may have the ability to introduce osteoinductive potential to a synthetic graft; however, although platelet–graft interactions may also exist [144], the optimal synthetic osteoconductive scaffold to use with PRP remains unclear. In contrast to autologous PRP, the commercial availability of recombinant growth factors allows for specific growth factors of known concentrations to be applied to bone defect sites, thus allowing the ability to consistently replicate positive outcomes. Recombinant BMP currently appears the most encouraging for bone healing. As the theoretical basis of PRP relies on the release of growth factors other than BMPs, the advantage of PRP application over rhBMP is uncertain. Hu et al. [145] demonstrated the potential of both PRP and rhBMP-4 to promote osteogenesis in vitro, however, this effect has not translated to ´ in vivo studies. Roldan et al. [146] compared rhBMP-7 and PRP, and reported that although the addition of rhBMP-7 to allograft was able to enhance bone formation, PRP combined with allograft was not. Similarly, Forriol et al. [147] reported PRP alone was inferior to rhBMP-7 combined with allograft. Although these studies report the benefit of recombinant BMP over PRP, the use of PRP combined with allograft, or PRP alone without an osteoconductive scaffold, has been shown not be conducive for PRP effectiveness. Further studies are needed which compare exogenous growth factor application and PRP. The combination of PRP and rhBMP should also be investigated.
  9. 9. Arch Orthop Trauma Surg (2013) 133:153–165 With the current focus on platelet concentration, the actual volume of PRP to use is often overlooked. Nagata et al. [116] detected healing differences relating to the ratio of autograft to PRP volume in critical size defects in rat calvaria; however, further comparative studies are needed to ascertain the optimal ratio of PRP volume to graft volume. Currently, the use of PRP may be most appropriate for bone healing when combined with a synthetic osteoconductive scaffold, reducing the need for allogenic products or autologous harvest of additional tissue or cells. Further research is required to provide more detailed clinical indication for use. Future directions The establishment of therapeutic doses of platelet concentration would aid greatly in guiding clinicians in treatments involving PRP. Ideally these would be in vivo animal studies that would allow in-depth analysis of bone regeneration capacity of comparative treatments with closely controlled conditions. PRP platelet concentrations are difficult to quantify in a clinical situations where coulter counters or other platelet counting mechanisms are not readily available. Currently, there are several variables involved in PRP preparation, making the supposed goal of 1,000 9 109/L difficult to insure, let alone achieve. Purely focusing on the concentration with disregard for the final PRP volume may also be distracting, as the volume of the bone void to be treated will affect the final concentration of platelets per bone void volume. This effect is not commonly mentioned, and should be considered. Many systems and studies still report the centrifugal force as revolutions per minute (RPM), although not reporting the relative centrifugal force (RCF). It is not possible to compare RPM from one study to another, as different models of centrifuges will have different rotational radii, making comparisons between methods and outcomes even more challenging. It is clear that standardization of terminology and methods would allow meaningful comparisons between future studies. The leukocyte concentration and fibrin structure vary between production and activation methods, and should be noted. The inherently safe, autologous nature of PRP has led to its adoption in an ever increasing range of applications; however, uncertainty in its efficacy does exist. A greater understanding of the mechanisms and variables involved may help explain the discrepancies seen in the translation from preclinical studies to clinical use. Theoretically, the potential of PRP is great. Despite completing an intensive and comprehensive literature research, there is a lack of evidence confirming any synergistic benefit of combining PRP to autograft or allograft. 161 However, the addition of PRP to synthetic bone graft substitutes (BGS) appears to be beneficial in some instances, and could be recommended if the alternative is the synthetic BGS alone. The use of PRP alone without any additional components does not appear to benefit bone healing, and cannot be recommended. With proper use, aseptic application of autologous PRP appears to safely provide access to growth factors that may be useful for bone healing. Further studies are needed to establish whether PRP combined with a synthetic BGS has a bone healing capacity comparable to autograft. Conflict of interest of interest. The authors declare that they have no conflict References 1. Novicoff WM, Manaswi A, Hogan MV, Brubaker SM, Mihalko WM, Saleh KJ (2008) Critical analysis of the evidence for current technologies in bone-healing and repair. J Bone Joint Surg Am 90(Suppl 1):85–91. doi:10.2106/JBJS.G.01521 2. Pape HC, Evans A, Kobbe P (2010) Autologous bone graft: properties and techniques. J Orthop Trauma 24(Suppl 1):S36– S40. doi:10.1097/BOT.0b013e3181cec4a1 3. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR (1998) Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85 (6):638–646 (pii:S1079-2104(98)90029-4) 4. Anitua E, Sanchez M, Orive G, Andia I (2009) Shedding light in the controversial terminology for platelet rich products. J Biomed Mater Res A 90(4):1262–1263. doi:10.1002/jbm.a.32143 5. Ehrenfest DM, Bielecki T, Del Corso M, Inchingolo F, Sammartino G (2010) Shedding light in the controversial terminology for platelet-rich products: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), platelet–leukocyte gel (PLG), preparation rich in growth factors (PRGF), classification and commercialism. J Biomed Mater Res A 95(4):1280–1282. doi: 10.1002/jbm.a.32894 6. Mora R, Pedrotti L, Battista Galli G (2006) Failure of Union. Nonunion of the long bones: diagnosis and treatment with compression: distraction techniques. Springer, Italy 7. Marsell R, Einhorn TA (2010) Emerging bone healing therapies. J Orthop Trauma 24(Suppl 1):S4–S8. doi:10.1097/BOT.0b013e 3181ca3fab 8. Einhorn TA (2005) The science of fracture healing. J Orthop Trauma 19(10 Suppl):S4–S6 9. Kolar P, Schmidt-Bleek K, Schell H, Gaber T, Toben D, Schmidmaier G, Perka C, Buttgereit F, Duda GN (2010) The early fracture hematoma and its potential role in fracture healing. Tissue Eng Part B Rev 16(4):427–434. doi:10.1089/ten.TEB.2009.0687 10. Mountziaris PM, Mikos AG (2008) Modulation of the inflammatory response for enhanced bone tissue regeneration. Tissue Eng Part B Rev 14(2):179–186. doi:10.1089/ten.teb.2008.0038 11. Lieberman JR, Daluiski A, Einhorn TA (2002) The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 84-A (6):1032–1044 12. Gaston MS, Simpson AH (2007) Inhibition of fracture healing. J Bone Joint Surg Br 89(12):1553–1560. doi:10.1302/0301620X.89B12.19671 13. Thon JN, Italiano JE (2010) Platelet formation. Seminars Hematol 47(3):220–226. doi:10.1053/j.seminhematol.2010.03.005 123
  10. 10. 162 14. Blair P, Flaumenhaft R (2009) Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 23(4):177–189. doi: 10.1016/j.blre.2009.04.001 15. Whiteheart SW (2011) Platelet granules: surprise packages. Blood 118(5):1190–1191. doi:10.1182/blood-2011-06-359836 16. Rendu F, Brohard-Bohn B (2001) The platelet release reaction: granules’ constituents, secretion and functions. Platelets 12(5): 261–273. doi:10.1080/09537100120068170 17. LeBaron RG, Athanasiou KA (2000) Extracellular matrix cell adhesion peptides: functional applications in orthopedic materials. Tissue Eng 6(2):85–103. doi:10.1089/107632700320720 18. Kempen DH, Creemers LB, Alblas J, Lu L, Verbout AJ, Yaszemski MJ, Dhert WJ (2010) Growth factor interactions in bone regeneration. Tissue Eng Part B Rev 16(6):551–566. doi: 10.1089/ten.teb.2010.0176 19. Perrault R, Wright B, Storie B, Hatherell A, Zahradka P (2011) Tyrosine kinase-independent activation of extracellular-regulated kinase (ERK) 1/2 by the insulin-like growth factor-1 receptor. Cell Signal 23(4):739–746. doi:10.1016/j.cellsig.2010. 12.008 20. Kawabata M, Imamura T, Miyazono K (1998) Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9(1):49–61 21. Bolsover SR, Hyams JS, Shephard EA, White HA, Wiedemann CG (2004) Intracellular Signaling. In: Cell Biology. Wiley, pp 341–362. doi:10.1002/047146158X.ch16 22. Rasubala L, Yoshikawa H, Nagata K, Iijima T, Ohishi M (2003) Platelet-derived growth factor and bone morphogenetic protein in the healing of mandibular fractures in rats. The British journal of oral & maxillofacial surgery 41(3):173–178 23. Ross R (1987) Platelet-derived growth factor. Ann Rev Med 38:71–79. doi:10.1146/ 24. Fujii H, Kitazawa R, Maeda S, Mizuno K, Kitazawa S (1999) Expression of platelet-derived growth factor proteins and their receptor alpha and beta mRNAs during fracture healing in the normal mouse. Histochem Cell Biol 112(2):131–138 25. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M (1994) PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 125(4):917–928 26. Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316 27. Caplan AI, Correa D (2011) PDGF in bone formation and regeneration: new insights into a novel mechanism involving MSCs. J Orthop Res 29(12):1795–1803. doi:10.1002/jor.21462 28. Hart CE, Bailey M, Curtis DA, Osborn S, Raines E, Ross R, Forstrom JW (1990) Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry 29(1):166–172 29. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267(16):10931–10934 30. Bauer SM, Bauer RJ, Velazquez OC (2005) Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg 39(4):293–306 31. Harmey JH (2004) VEGF and Cancer. Kluwer Academic/Plenum Publishers, New York 32. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5(6):623–628. doi:10.1038/9467 33. Maloney JP, Silliman CC, Ambruso DR, Jun Wang RMT, Voelkel NF (1998) In vitro release of vascular endothelial growth factor during platelet aggregation Am J Physiol Heart Circ Physiol 275 (3):1054–1061 34. Battinelli EM, Markens BA, Italiano JE Jr (2011) Release of angiogenesis regulatory proteins from platelet alpha granules: 123 Arch Orthop Trauma Surg (2013) 133:153–165 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. modulation of physiologic and pathologic angiogenesis. Blood 118(5):1359–1369. doi:10.1182/blood-2011-02-334524 Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111(3): 1227–1233. doi:10.1182/blood-2007-09-113837 Sulpice E, Ding S, Muscatelli-Groux B, Berge M, Han ZC, Plouet J, Tobelem G, Merkulova-Rainon T (2009) Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol cell/Auspices Eur Cell Biol Organ 101(9): 525–539. doi:10.1042/BC20080221 Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158(3):1111–1120. doi: 10.1016/S0002-9440(10)64058-8 Wen Q, Zhou L, Zhou C, Zhou M, Luo W, Ma L (2011) Change in hepatocyte growth factor concentration promote mesenchymal stem cell-mediated osteogenic regeneration [Abstract]. J Cell Mol Med. doi:10.1111/j.1582-4934.2011.01407.x Imai Y, Terai H, Nomura-Furuwatari C, Mizuno S, Matsumoto K, Nakamura T, Takaoka K (2005) Hepatocyte growth factor contributes to fracture repair by upregulating the expression of BMP receptors. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20(10):1723–1730. doi:10.1359/JBMR.050607 Heldin CH, Miyazono K, ten Dijke P (1997) TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390(6659):465–471. doi:10.1038/37284 Patil AS, Sable RB, Kothari RM (2011) An update on transforming growth factor-beta (TGF-beta): sources, types, functions and clinical applicability for cartilage/bone healing. J Cell Physiol. doi:10.1002/jcp.22698 Joyce ME, Roberts AB, Sporn MB, Bolander ME (1990) Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 110(6):2195–2207 Horner A, Kemp P, Summers C, Bord S, Bishop NJ, Kelsall AW, Coleman N, Compston JE (1998) Expression and distribution of transforming growth factor-beta isoforms and their signaling receptors in growing human bone. Bone 23(2):95–102 Yu Y, Yang JL, Chapman-Sheath PJ, Walsh WR (2002) TGFbeta, BMPs, and their signal transducing mediators, Smads, in rat fracture healing. J Biomed Mater Res 60(3):392–397 Zhao L, Jiang S, Hantash BM (2010) Transforming growth factor beta1 induces osteogenic differentiation of murine bone marrow stromal cells. Tissue Eng Part A 16(2):725–733. doi: 10.1089/ten.TEA.2009.0495 Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V (2008) PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112(2):295–307. doi:10.1182/blood-2007-07-103697 Houde N, Chamoux E, Bisson M, Roux S (2009) Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J Biol Chem 284(35):23397– 23404. doi:10.1074/jbc.M109.019372 Cho TJ, Gerstenfeld LC, Einhorn TA (2002) Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. J Bone Miner Res Official J Am Soc Bone Miner Res 17(3):513–520. doi: 10.1359/jbmr.2002.17.3.513
  11. 11. Arch Orthop Trauma Surg (2013) 133:153–165 49. Urist MR (1965) Bone: formation by autoinduction. Science 150(698):893–899 50. Schmitt JM, Hwang K, Winn SR, Hollinger JO (1999) Bone morphogenetic proteins: an update on basic biology and clinical relevance. J Orthop Res 17(2):269–278. doi:10.1002/jor.1100170217 51. Kaipel M, Schutzenberger S, Schultz A, Ferguson J, Slezak P, Morton TJ, Van Griensven M, Redl H (2012) BMP-2 but not VEGF or PDGF in fibrin matrix supports bone healing in a delayed-union rat model. J Orthop Res. doi:10.1002/jor.22132 52. Sakou T (1998) Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 22(6):591–603 53. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A (8):1544–1552 54. Kalen A, Wahlstrom O, Linder CH, Magnusson P (2008) The content of bone morphogenetic proteins in platelets varies greatly between different platelet donors. Biochem Biophys Res Commun 375(2):261–264. doi:10.1016/j.bbrc.2008.08.014 55. Marx RE (2004) Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 62 (4):489–496 (pii: S0278239103 012722) 56. Wahlstrom O, Linder C, Kalen A, Magnusson P (2008) Acidic preparations of platelet concentrates release bone morphogenetic protein-2. Acta Orthop 79(3):433–437. doi:10.1080/1745 3670710015364 57. Zegzula HD, Buck DC, Brekke J, Wozney JM, Hollinger JO (1997) Bone formation with use of rhBMP-2 (recombinant human bone morphogenetic protein-2). J Bone Joint Surg Am 79(12):1778–1790 58. Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, Kregor PJ, Nordsletten L, Paiement G, Patel A (2006) Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 88(6):1258–1265. doi:10.2106/JBJS.E.00499 59. Fei Y, Xiao L, Doetschman T, Coffin DJ, Hurley MM (2011) Fibroblast growth factor 2 stimulation of osteoblast differentiation and bone formation is mediated by modulation of the Wnt signaling pathway. J Biol Chem 286(47):40575–40583. doi: 10.1074/jbc.M111.274910 60. Tavakoli K, Yu Y, Shahidi S, Bonar F, Walsh WR, Poole MD (1999) Expression of growth factors in the mandibular distraction zone: a sheep study. Br J Plast Surg 52(6):434–439. doi: 10.1054/bjps.1999.3157 61. Nakajima A, Nakajima F, Shimizu S, Ogasawara A, Wanaka A, Moriya H, Einhorn TA, Yamazaki M (2001) Spatial and temporal gene expression for fibroblast growth factor type I receptor (FGFR1) during fracture healing in the rat. Bone 29(5):458–466 62. Marie PJ, Miraoui H, Severe N (2012) FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors. doi: 10.3109/08977194.2012.656761 63. Beenken A, Mohammadi M (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3):235–253. doi:10.1038/nrd2792 64. Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453(7193):314–321. doi: 10.1038/nature07039 65. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92 (9 Suppl): II365–371 66. Willems WF, Larsen M, Giusti G, Friedrich PF, Bishop AT (2011) Revascularization and bone remodeling of frozen 163 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. allografts stimulated by intramedullary sustained delivery of FGF-2 and VEGF. J Orthop Res 29(9):1431–1436. doi: 10.1002/jor.21338 Fisher MC, Meyer C, Garber G, Dealy CN (2005) Role of IGFBP2, IGF-I and IGF-II in regulating long bone growth. Bone 37(6):741–750. doi:10.1016/j.bone.2005.07.024 Zhou FH, Foster BK, Sander G, Xian CJ (2004) Expression of proinflammatory cytokines and growth factors at the injured growth plate cartilage in young rats. Bone 35(6):1307–1315. doi:10.1016/j.bone.2004.09.014 Clark RA (2001) Fibrin and wound healing. Ann N Y Acad Sci 936:355–367 Laurens N, Koolwijk P, de Maat MP (2006) Fibrin structure and wound healing. J Thromb Haemost 4(5):932–939. doi:10.1111/ j.1538-7836.2006.01861.x Jacek H (1989) [15] Platelet secretory pathways: an overview. In: Methods in Enzymology, vol Volume 169. Academic Press, pp 191–195. doi:10.1016/0076-6879(89)69059-3 ´ Santos-Martınez MJ, Medina C, Jurasz P, Radomski MW (2008) Role of metalloproteinases in platelet function. Thrombosis Res 121(4):535–542. doi:10.1016/j.thromres.2007.06.002 Marzona L, Pavolini B (2009) Play and players in bone fracture healing match. Clin Cases Mineral Bone Metabolism 6(2): 159–162 Phillips AM (2005) Overview of the fracture healing cascade. Injury 36(Suppl 3):S5–S7. doi:10.1016/j.injury.2005.07.027 Alsousou J, Thompson M, Hulley P, Noble A, Willett K (2009) The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 91(8):987–996. doi:10.1302/0301-620X.91B8.22546 Lee FY, Choi YW, Behrens FF, DeFouw DO, Einhorn TA (1998) Programmed removal of chondrocytes during endochondral fracture healing. J Orthop Res 16(1):144–150. doi: 10.1002/jor.1100160124 Gutwald R, Haberstroh J, Stricker A, Ruther E, Otto F, Xavier SP, Oshima T, Marukawa E, Seto I, Enomoto S, Hoogendijk CF, Schmelzeisen R, Sauerbier S (2010) Influence of rhBMP-2 on bone formation and osseointegration in different implant systems after sinus-floor elevation. An in vivo study on sheep. J Craniomaxillofac Surg. doi:10.1016/j.jcms.2010.02.010 Sumner DR, Turner TM, Urban RM, Turek T, Seeherman H, Wozney JM (2004) Locally delivered rhBMP-2 enhances bone ingrowth and gap healing in a canine model. J Orthop Res 22(1):58–65. doi:10.1016/S0736-0266(03)00127-X Schutzenberger S, Schultz A, Hausner T, Hopf R, Zanoni G, Morton T, Kropik K, van Griensven M, Redl H (2012) The optimal carrier for BMP-2: a comparison of collagen versus fibrin matrix. Archives Orthop Trauma Surg 132(9):1363–1370. doi:10.1007/s00402-012-1551-2 Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A (2006) Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88(7):1431–1441. doi:10.2106/JBJS.E.00381 Aro HT, Govender S, Patel AD, Hernigou P, de Gregorio AP, Popescu GI, Golden JD, Christensen J, Valentin A (2011) Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J Bone Joint Surg Am 93(9):801–808. doi:10.2106/JBJS.I.01763 Seeherman HJ, Li XJ, Bouxsein ML, Wozney JM (2010) rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 92(2):411–426. doi:10.2106/JBJS.H.01732 Moore DC, Ehrlich MG, McAllister SC, Machan JT, Hart CE, Voigt C, Lesieur-Brooks AM, Weber EW (2009) Recombinant 123
  12. 12. 164 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. Arch Orthop Trauma Surg (2013) 133:153–165 human platelet-derived growth factor-BB augmentation of newbone formation in a rat model of distraction osteogenesis. J Bone Joint Surg Am 91(8):1973–1984. doi:10.2106/JBJS.H.00540 Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ (1994) Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 15(2):203–208 Solchaga LA, Hee CK, Aguiar DJ, Ratliff J, Turner AS, Seim HB, 3rd, Hollinger JO, Snel LB, Lynch SE (2012) Augment bone graft products compare favorably with autologous bone graft in an ovine model of lumbar interbody spine fusion. Spine (Phila Pa 1976) 37 (8):E461–467. doi:10.1097/BRS.0b013e318 23b01dc Hollinger JO, Onikepe AO, MacKrell J, Einhorn T, Bradica G, Lynch S, Hart CE (2008) Accelerated fracture healing in the geriatric, osteoporotic rat with recombinant human plateletderived growth factor-BB and an injectable beta-tricalcium phosphate/collagen matrix. J Orthop Res 26(1):83–90. doi: 10.1002/jor.20453 Brennan M (1991) Fibrin glue. Blood Rev 5(4):240–244 Tayapongsak P, O’Brien DA, Monteiro CB, Arceo-Diaz LY (1994) Autologous fibrin adhesive in mandibular reconstruction with particulate cancellous bone and marrow. J Oral Maxillofac Surg 52 (2):161–165; discussion 166 Anitua E (1999) Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 14(4):529–535 Landesberg R, Roy M, Glickman RS (2000) Quantification of growth factor levels using a simplified method of platelet-rich plasma gel preparation. J Oral Maxillofac Surg 58 (3):297–300; discussion 300–291 (pii:S0278-2391(00)90058-2) Kassolis JD, Rosen PS, Reynolds MA (2000) Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze-dried bone allograft: case series. J Periodontol 71(10):1654–1661. doi:10.1902/jop.2000.71.10.1654 Borrione P, Gianfrancesco AD, Pereira MT, Pigozzi F (2010) Platelet-rich plasma in muscle healing. Am J Phys Med Rehabil 89(10):854–861. doi:10.1097/PHM.0b013e3181f1c1c7 de Vos RJ, van Veldhoven PL, Moen MH, Weir A, Tol JL, Maffulli N (2010) Autologous growth factor injections in chronic tendinopathy: a systematic review. Br Med Bull 95:63– 77. doi:10.1093/bmb/ldq006 Cervelli V, Gentile P, Scioli MG, Grimaldi M, Casciani CU, Spagnoli LG, Orlandi A (2009) Application of platelet-rich plasma in plastic surgery: clinical and in vitro evaluation. Tissue Eng Part C Methods 15(4):625–634. doi:10.1089/ten.TEC.2008. 0518 Man D, Plosker H, Winland-Brown JE (2001) The use of autologous platelet-rich plasma (platelet gel) and autologous platelet-poor plasma (fibrin glue) in cosmetic surgery. Plast Reconstr Surg 107:229–237 Pallua N, Wolter T, Markowicz M (2010) Platelet-rich plasma in burns. Burns 36(1):4–8. doi:10.1016/j.burns.2009.05.002 Ding XG, Li SW, Zheng XM, Hu LQ, Hu WL, Luo Y (2009) The effect of platelet-rich plasma on cavernous nerve regeneration in a rat model. Asian J Androl 11(2):215–221. doi:10.1038/ aja.2008.37 Shen YX, Fan ZH, Zhao JG, Zhang P (2009) The application of platelet-rich plasma may be a novel treatment for central nervous system diseases. Med Hypotheses 73(6):1038–1040. doi: 10.1016/j.mehy.2009.05.021 Villela DL, Santos VL (2010) Evidence on the use of plateletrich plasma for diabetic ulcer: a systematic review. Growth Factors 28(2):111–116. doi:10.3109/08977190903468185 May JA, Heptinstall S (2004) Effects of anticoagulants used during blood collection on human platelet function. Methods Mol Biol 272:3–11. doi:10.1385/1-59259-782-3:003 123 101. Pignatelli P, Pulcinelli FM, Ciatti F, Pesciotti M, Sebastiani S, Ferroni P, Gazzaniga PP (1995) Acid citrate dextrose (ACD) formula A as a new anticoagulant in the measurement of in vitro platelet aggregation. J Clin Lab Anal 9(2):138–140 102. Araki J, Jona M, Eto H, Aoi N, Kato H, Suga H, Doi K, Yatomi Y, Yoshimura K (2011) Optimized preparation method of platelet-concentrated plasma and noncoagulating plateletderived factor concentrates: maximization of platelet concentration and removal of fibrinogen. Tissue Eng Part C Methods. doi:10.1089/ten.TEC.2011.0308 103. White JG (2000) EDTA-induced changes in platelet structure and function: clot retraction. Platelets 11(1):49–55 104. Zimmermann R, Reske S, Metzler P, Schlegel A, Ringwald J, Eckstein R (2008) Preparation of highly concentrated and white cell-poor platelet-rich plasma by plateletpheresis. Vox Sang 95(1):20–25. doi:10.1111/j.1423-0410.2008.01062.x 105. Everts PA, Brown Mahoney C, Hoffmann JJ, Schonberger JP, Box HA, van Zundert A, Knape JT (2006) Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors 24(3):165–171. doi:10.1080/08977190600821327 106. Marx RE (2001) Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 10(4):225–228 107. Kaux JF, Le Goff C, Renouf J, Peters P, Lutteri L, Gothot A, Crielaard JM (2010) Comparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS II and GPS III systems. Pathologie-biologie. doi:10.1016/j.patbio.2010.11.002 108. Castillo TN, Pouliot MA, Kim HJ, Dragoo JL (2011) Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med 39(2):266–271. doi:10.1177/0363546510387517 109. Dohan Ehrenfest DM, Rasmusson L, Albrektsson T (2009) Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). Trends Biotechnol 27(3):158–167. doi:10.1016/j.tibtech.2008. 11.009 110. Mehta S, Watson JT (2008) Platelet rich concentrate: basic science and current clinical applications. J Orthop Trauma 22(6):432–438. doi:10.1097/BOT.0b013e31817e793f 111. Dugrillon A, Eichler H, Kern S, Kluter H (2002) Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. Int J Oral Maxillofac Surg 31(6):615–619. doi:10.1054/ijom.2002.0322 112. Weibrich G, Hansen T, Kleis W, Buch R, Hitzler WE (2004) Effect of platelet concentration in platelet-rich plasma on periimplant bone regeneration. Bone 34(4):665–671. doi:10.1016/ j.bone.2003.12.010 113. Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M (2006) The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 17(2): 212–219. doi:10.1111/j.1600-0501.2005.01203.x 114. Nikolidakis D, Jansen JA (2008) The biology of platelet-rich plasma and its application in oral surgery: literature review. Tissue Eng Part B Rev 14(3):249–258. doi:10.1089/ten.teb. 2008.0062 115. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH (2001) Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233(1):88–96 116. Nagata MJ, Messora M, Pola N, Campos N, Vieira R, Esper LA, Sbrana M, Fucini S, Garcia V, Bosco A (2010) Influence of the ratio of particulate autogenous bone graft/platelet-rich plasma on bone healing in critical-size defects: a histologic and histometric study in rat calvaria. J Orthop Res 28(4):468–473. doi: 10.1002/jor.21027 117. Wolberg AS (2007) Thrombin generation and fibrin clot structure. Blood Rev 21(3):131–142. doi:10.1016/j.blre.2006.11.001
  13. 13. Arch Orthop Trauma Surg (2013) 133:153–165 118. Weisel JW (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5(Suppl 1):116–124. doi:10.1111/j.15387836.2007.02504.x 119. Everts PA, Hoffmann J, Weibrich G, Mahoney CB, Schonberger JP, van Zundert A, Knape JT (2006) Differences in platelet growth factor release and leucocyte kinetics during autologous platelet gel formation. Transfus Med 16(5):363–368. doi: 10.1111/j.1365-3148.2006.00708.x 120. Cieslik-Bielecka A, Gazdzik TS, Bielecki TM, Cieslik T (2007) Why the platelet-rich gel has antimicrobial activity? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103 (3):303–305; author reply 305–306. doi:10.1016/j.tripleo.2006.08.034 121. Werther K, Christensen IJ, Nielsen HJ (2002) Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 62(5):343–350 122. Flad HD, Brandt E (2010) Platelet-derived chemokines: pathophysiology and therapeutic aspects. Cell Mol Life Sci. doi: 10.1007/s00018-010-0306-x 123. Tang YQ, Yeaman MR, Selsted ME (2002) Antimicrobial peptides from human platelets. Infect Immun 70(12):6524–6533 124. Moojen DJ, Everts PA, Schure RM, Overdevest EP, van Zundert A, Knape JT, Castelein RM, Creemers LB, Dhert WJ (2008) Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res 26(3):404–410. doi:10.1002/ jor.20519 125. Sanchez M, Anitua E, Orive G, Mujika I, Andia I (2009) Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med 39(5):345–354. doi:10.2165/00007256200939050-00002 126. Delong JM, Russell RP, Mazzocca AD (2012) Platelet-rich plasma: the PAW classification system. Arthroscopy 28(7):998–1009. doi:10.1016/j.arthro.2012.04.148 127. Langer R, Vacanti JP (1993) Tissue engineering. Science 260(5110):920–926 128. Hokugo A, Ozeki M, Kawakami O, Sugimoto K, Mushimoto K, Morita S, Tabata Y (2005) Augmented bone regeneration activity of platelet-rich plasma by biodegradable gelatin hydrogel. Tissue Eng 11(7–8):1224–1233. doi:10.1089/ten.2005. 11.1224 129. Zimmermann G, Moghaddam A (2011) Allograft bone matrix versus synthetic bone graft substitutes. Injury. doi:10.1016/ j.injury.2011.06.199 130. Ranly DM, Lohmann CH, Andreacchio D, Boyan BD, Schwartz Z (2007) Platelet-rich plasma inhibits demineralized bone matrix-induced bone formation in nude mice. J Bone Joint Surg Am 89(1):139–147. doi:10.2106/JBJS.F.00388 131. Ni M, Tang P, Wang Y, Li G (2011) Experimental study on promoting bone consolidation by using platelet-rich plasma and decalcified bone matrix during distraction osteogenesis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 25(6):661–667 132. Myeroff C, Archdeacon M (2011) Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am 93(23):2227–2236. doi:10.2106/JBJS.J.01513 133. Mooren RE, Merkx MA, Bronkhorst EM, Jansen JA, Stoelinga PJ (2007) The effect of platelet-rich plasma on early and late bone healing: an experimental study in goats. Int J Oral Maxillofac Surg 36(7):626–631. doi:10.1016/j.ijom.2007.03.013 134. Mooren RE, Dankers AC, Merkx MA, Bronkhorst EM, Jansen JA, Stoelinga PJ (2010) The effect of platelet-rich plasma on 165 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. early and late bone healing using a mixture of particulate autogenous cancellous bone and Bio-Oss: an experimental study in goats. Int J Oral Maxillofac Surg 39(4):371–378. doi:10.1016/ j.ijom.2009.12.019 Aghaloo TL, Moy PK, Freymiller EG (2002) Investigation of platelet-rich plasma in rabbit cranial defects: a pilot study. J Oral Maxillofac Surg 60(10):1176–1181 Dallari D, Fini M, Stagni C, Torricelli P, Nicoli Aldini N, Giavaresi G, Cenni E, Baldini N, Cenacchi A, Bassi A, Giardino R, Fornasari PM, Giunti A (2006) In vivo study on the healing of bone defects treated with bone marrow stromal cells, plateletrich plasma, and freeze-dried bone allografts, alone and in combination. J Orthop Res 24(5):877–888. doi:10.1002/jor. 20112 Hakimi M, Jungbluth P, Sager M, Betsch M, Herten M, Becker J, Windolf J, Wild M (2010) Combined use of platelet-rich plasma and autologous bone grafts in the treatment of long bone defects in mini-pigs. Injury 41(7):717–723. doi:10.1016/ j.injury.2009.12.005 Walsh WR, Vizesi F, Michael D, Auld J, Langdown A, Oliver R, Yu Y, Irie H, Bruce W (2008) b-TCP bone graft substitutes in a bilateral rabbit tibial defect model. Biomaterials 29(3): 266–271 Yuan H, Fernandes H, Habibovic P, de Boer J, Barradas AM, de Ruiter A, Walsh WR, van Blitterswijk CA, de Bruijn JD (2010) Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. Proc Natl Acad Sci USA 107(31):13614–13619. doi:10.1073/pnas.1003600107 Kasten P, Vogel J, Geiger F, Niemeyer P, Luginbuhl R, Szalay K (2008) The effect of platelet-rich plasma on healing in critical-size long-bone defects. Biomaterials 29(29):3983–3992. doi: 10.1016/j.biomaterials.2008.06.014 Kanthan SR, Kavitha G, Addi S, Choon DS, Kamarul T (2011) Platelet-rich plasma (PRP) enhances bone healing in non-united critical-sized defects: a preliminary study involving rabbit models. Injury 42(8):782–789. doi:10.1016/j.injury.2011.01.015 Paderni S, Terzi S, Amendola L (2009) Major bone defect treatment with an osteoconductive bone substitute. Musculoskelet Surg 93(2):89–96. doi:10.1007/s12306-009-0028-0 Walsh WR, Loefler A, Nicklin S, Arm D, Stanford RE, Yu Y, Harris R, Gillies RM (2004) Spinal fusion using an autologous growth factor gel and a porous resorbable ceramic. Eur Spine J 13(4):359–366. doi:10.1007/s00586-003-0597-9 Klein MO, Kammerer PW, Scholz T, Moergel M, Kirchmaier CM, Al-Nawas B (2010) Modulation of platelet activation and initial cytokine release by alloplastic bone substitute materials. Clin Oral Implants Res. doi:10.1111/j.1600-0501.2009.01830.x Hu ZM, Peel SA, Ho SK, Sandor GK, Clokie CM (2009) Comparison of platelet-rich plasma, bovine BMP, and rhBMP-4 on bone matrix protein expression in vitro. Growth Factors 27(5):280–288. doi:10.1080/08977190903137819 Roldan JC, Jepsen S, Miller J, Freitag S, Rueger DC, Acil Y, Terheyden H (2004) Bone formation in the presence of plateletrich plasma versus bone morphogenetic protein-7. Bone 34(1):80–90 Forriol F, Longo UG, Concejo C, Ripalda P, Maffulli N, Denaro V (2009) Platelet-rich plasma, rhOP-1 (rhBMP-7) and frozen rib allograft for the reconstruction of bony mandibular defects in sheep. a pilot experimental study. Injury 40(Suppl 3):S44–S49. doi:10.1016/S0020-1383(09)70011-7 123